Article Details
Retrieved on: 2020-11-23 00:00:00
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
ORIENT-32 is the first randomized Phase 3 study reporting the efficacy and safety of an anti-PD-1 <b>antibody</b>-based combination therapy versus ...
Article found on: finance.yahoo.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here